Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CYCLONE 1 trial: what clinicians have said so far
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
- NCT04408924 ↗
- Completed
- Eli Lilly and Company
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CYCLONE 1 (abemaciclib in heavily treated metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CYCLONE 1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 podcast episodes, typically up to 9 once built | |
| 2 posts on X, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Abemaciclib
- Arms
- 200 milligram (mg) Abemaciclib Twice Daily · Experimental
- Enrollment
- 44
- Primary outcomes
- Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])
- Sponsor
- Eli Lilly and Company
- Start
- Jan 20, 2021
- Primary completion
- Apr 27, 2022
- Results posted
- Yes
- Registry record
- NCT04408924 · updated Jun 25, 2024